150 related articles for article (PubMed ID: 20652120)
1. Topical Imiquimod Treatment of Lentigo Maligna.
Ventura F; Rocha J; Fernandes JC; Pardal F; Brito C
Case Rep Dermatol; 2009 Oct; 1(1):78-81. PubMed ID: 20652120
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lentigo maligna with imiquimod 5% cream.
Hopson B; Richey D; Sajben FP
J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
[TBL] [Abstract][Full Text] [Related]
4. Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature.
Vaienti S; Calzari P; Nazzaro G
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2187-2215. PubMed ID: 37615838
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod: a novel treatment for lentigo maligna.
Ahmed I; Berth-Jones J
Br J Dermatol; 2000 Oct; 143(4):843-5. PubMed ID: 11069469
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
8. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
9. [Lentigo maligna treated with 5% imiquimod cream].
Martín T; Ojeda A; Martínez S; Vera A
Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
[TBL] [Abstract][Full Text] [Related]
10. Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma.
Matas-Nadal C; Sòria X; García-de-la-Fuente MR; Huerva V; Ortega E; Vilardell F; Gatius S; Casanova JM; Martí RM
J Dermatol; 2018 May; 45(5):564-570. PubMed ID: 29430695
[TBL] [Abstract][Full Text] [Related]
11. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
[TBL] [Abstract][Full Text] [Related]
12. Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna.
Robinson M; Primiero C; Guitera P; Hong A; Scolyer RA; Stretch JR; Strutton G; Thompson JF; Soyer HP
Dermatology; 2020; 236(2):111-116. PubMed ID: 31639788
[TBL] [Abstract][Full Text] [Related]
13. Lentigo Maligna on a Difficult Location of the Face Treated with 5% Imiquimod: A Case Report of 2-Year Follow-Up.
Misiak-Galazka M; Czuwara J; Galazka A; Czaplicka A; Rudnicka L
Dermatol Ther (Heidelb); 2022 Feb; 12(2):599-604. PubMed ID: 35083713
[TBL] [Abstract][Full Text] [Related]
14. Lentigo Maligna: Clinical Presentation and Appropriate Management.
Iznardo H; Garcia-Melendo C; Yélamos O
Clin Cosmet Investig Dermatol; 2020; 13():837-855. PubMed ID: 33223843
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
Powell AM; Robson AM; Russell-Jones R; Barlow RJ
Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lentigo maligna with topical imiquimod.
Naylor MF; Crowson N; Kuwahara R; Teague K; Garcia C; Mackinnis C; Haque R; Odom C; Jankey C; Cornelison RL
Br J Dermatol; 2003 Nov; 149 Suppl 66():66-70. PubMed ID: 14616356
[TBL] [Abstract][Full Text] [Related]
17. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
Donigan JM; Hyde MA; Goldgar DE; Hadley ML; Bowling M; Bowen GM
JAMA Dermatol; 2018 Aug; 154(8):885-889. PubMed ID: 29847610
[TBL] [Abstract][Full Text] [Related]
18. Conservative treatment of lentigo maligna with topical imiquimod 5% cream: a case report.
Lobo Y; Templeman R
Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898412
[TBL] [Abstract][Full Text] [Related]
19. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
